Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study - 31/12/20
the International Watch & Wait Database Consortium*
Summary |
Background |
Watch and wait is a novel management strategy in patients with rectal cancer who have a clinical complete response after neoadjuvant chemoradiotherapy. Surveillance of these patients is generally intensive, because local regrowth (with the potential for salvage) occurs in 25% of patients, and distant metastases occur in 10% of patients. It is unclear for how long these patients should be followed up. To address this issue, we did conditional survival modelling using the International Watch & Wait Database (IWWD), which is a large-scale registry of patients with a clinical complete response after neoadjuvant chemotherapy who have been managed by a watch-and-wait strategy.
Methods |
We did a retrospective, multicentre registry study using a dataset from the IWWD, which includes data from 47 clinics across 15 countries. We selected patients (aged ≥18 years) with rectal cancer who had a clinical complete response after neoadjuvant chemotherapy, and who were subsequently managed by a watch-and-wait strategy between Nov 25, 1991, and Dec 31, 2015. Patients who had not achieved a clinical complete response or who had undergone any surgical procedure were excluded. The criteria used for defining a clinical complete response and the specific surveillance strategies were at the discretion of each participating centre. We used conditional survival modelling to estimate the probability of patients remaining free of local regrowth or distant metastasis for an additional 2 years after sustaining a clinical complete response or being distant metastasis-free for 1, 3, and 5 years from the date of the decision to commence watch and wait. The primary outcomes were conditional local regrowth-free survival at 3 years, and conditional distant metastasis-free survival at 5 years.
Findings |
We identified 793 patients in the IWWD with clinical complete response who had been managed by a watch-and-wait strategy. Median follow-up was 55·2 months (IQR 36·0–75·6). The probability of remaining free from local regrowth for an additional 2 years if a patient had a sustained clinical complete response for 1 year was 88·1% (95% CI 85·8–90·9), for 3 years was 97·3% (95·2–98·6), and for 5 years was 98·6% (97·6–100·0). The probably of remaining free from distant metastasis for a further 2 years in patients who had a clinical complete response without distant metastasis for 1 year was 93·8% (92·3–95·9), for 3 years was 97·8% (96·6–99·3), and for 5 years was 96·6% (94·0–98·9).
Interpretation |
These results suggest that the intensity of active surveillance in patients with rectal cancer managed by a watch-and-wait approach could be reduced if they achieve and maintain a clinical complete response within the first 3 years of starting this approach.
Funding |
European Registration of Cancer Care, financed by the European Society of Surgical Oncology, the Champalimaud Foundation Lisbon, the Bas Mulder Award, granted by the Alpe d’HuZes Foundation and the Dutch Cancer Society, the European Research Council Advanced Grant, and the National Institute of Health and Research Manchester Biomedical Research Centre.
Le texte complet de cet article est disponible en PDF.Plan
Vol 22 - N° 1
P. 43-50 - janvier 2021 Retour au numéro
Article précédent
- Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
- Renu R Bahadoer, Esmée A Dijkstra, Boudewijn van Etten, Corrie A M Marijnen, Hein Putter, Elma Meershoek-Klein Kranenbarg, Annet G H Roodvoets, Iris D Nagtegaal, Regina G H Beets-Tan, Lennart K Blomqvist, Tone Fokstuen, Albert J ten Tije, Jaume Capdevila, Mathijs P Hendriks, Ibrahim Edhemovic, Andrés Cervantes, Per J Nilsson, Bengt Glimelius, Cornelis J H van de Velde, Geke A P Hospers, the RAPIDO collaborative investigators, L. Østergaard, F. Svendsen Jensen, P. Pfeiffer, K.E.J. Jensen, M.P. Hendriks, W.H. Schreurs, H.P. Knol, J.J. van der Vliet, J.B. Tuynman, A.M.E. Bruynzeel, E.D. Kerver, S. Festen, M.E. van Leerdam, G.L. Beets, L.G.H. Dewit, C.J.A. Punt, P.J. Tanis, E.D. Geijsen, P. Nieboer, W.A. Bleeker, A.J. Ten Tije, R.M.P.H. Crolla, A.C.M. van de Luijtgaarden, J.W.T. Dekker, J.M. Immink, F.J.F. Jeurissen, A.W.K.S. Marinelli, H.M. Ceha, T.C. Stam, P. Quarles an Ufford, W.H. Steup, A.L.T. Imholz, R.J.I. Bosker, J.H.M. Bekker, G.J. Creemers, G.A.P. Nieuwenhuijzen, H. van den Berg, W.M. van der Deure, R.F. Schmitz, J.M. van Rooijen, A.F.T. Olieman, A.C.M. van den Bergh, D.J.A. de Groot, K. Havenga, J.C. Beukema, J. de Boer, P.H.J.M. Veldman, E.J.M. Siemerink, J.W.P. Vanstiphout, B. de Valk, Q.A.J. Eijsbouts, M.B. Polée, C. Hoff, A. Slot, H.W. Kapiteijn, K.C.M.J. Peeters, F.P. Peters, P.A. Nijenhuis, S.A. Radema, H. de Wilt, P. Braam, G.J. Veldhuis, D. Hess, T. Rozema, O. Reerink, D. Ten Bokkel Huinink, A. Pronk, J. Vos, M. Tascilar, G.A. Patijn, C. Kersten, O. Mjåland, M. Grønlie Guren, A.N. Nesbakken, J. Benedik, I. Edhemovic, V. Velenik, J. Capdevila, E. Espin, R. Salazar, S. Biondo, V. Pachón, J. die Trill, J. Aparicio, E. Garcia Granero, M.J. Safont, J.C. Bernal, A. Cervantes, A. Espí Macías, L. Malmberg, G. Svaninger, H. Hörberg, G. Dafnis, A. Berglund, L. Österlund, K. Kovacs, J. Hol, S. Ottosson, G. Carlsson, C. Bratthäll, J. Assarsson, B.L. Lödén, P. Hede, I. Verbiené, O. Hallböök, A. Johnsson, M.L. Lydrup, K. Villmann, P. Matthiessen, J.H. Svensson, J. Haux, S. Skullman, T. Fokstuen, T. Holm, P. Flygare, M. Walldén, B. Lindh, O. Lundberg, C. Radu, L. Påhlman, A. Piwowar, K. Smedh, U. Palenius, S. Jangmalm, P. Parinkh, H. Kim, M.L. Silviera
- Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
- Jonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay V Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares, CASPIAN investigators, Mikhail Dvorkin, Dmytro Trukhin, Galina Statsenko, Nataliia Voitko, Artem Poltoratskiy, Igor Bondarenko, Yuanbin Chen, Andrzej Kazarnowicz, Luis Paz-Ares, Mustafa Özgüroglu, Nikolay Conev, Maximilian Hochmair, Otto Burghuber, Libor Havel, Irfan Çiçin, György Losonczy, Vladimir Moiseenko, Mustafa Erman, Dariusz Kowalski, Marek Wojtukiewicz, Hryhoriy Adamchuk, Alexander Vasilyev, Serhii Shevnia, Spartak Valev, Niels Reinmuth, Jun Ho Ji, Maria Amelia Insa Molla, Grygorii Ursol, Anne Chiang, Sylvia Hartl, Zsolt Horváth, Gábor Pajkos, Francesco Verderame, Katsuyuki Hotta, Sang-We Kim, Alexey Smolin, Tuncay Göksel, Shaker Dakhil, Jaromir Roubec, Krisztina Bogos, Marina Chiara Garassino, Robin Cornelissen, Jong-Seok Lee, Maria Rosario Garcia Campelo, Marta Lopez Brea, Ahmet Alacacioglu, Ignacio Casarini, Rumyana Ilieva, Ivan Tonev, Attila Somfay, Jair Bar, Alona Zer Kuch, Mauro Minelli, Roberta Bartolucci, Fausto Roila, Haruhiro Saito, Koichi Azuma, Gyeong-Won Lee, Alexander Luft, Michal Urda, Juan Ignacio Delgado Mingorance, Margarita Majem Tarruella, David Spigel, Krassimir Koynov, Milada Zemanova, Jens Panse, Christian Schulz, Zsolt Pápai Székely, Veronika Sárosi, Angelo Delmonte, Anna Cecilia Bettini, Makoto Nishio, Isamu Okamoto, Lizza Hendriks, Slawomir Mandziuk, Yun Gyoo Lee, Lyubov Vladimirova, Dolores Isla Casado, Manuel Domine Gomez, Alejandro Navarro Mendivil, Teresa Morán Bueno, Shang-Yin Wu, Jeanna Knoble, Jana Skrickova, Violetka Venkova, Werner Hilgers, Eckart Laack, Helge Bischoff, Andrea Fülöp, Ibolya Laczó, Judit Kósa, András Telekes, Tatsuya Yoshida, Shintaro Kanda, Toyoaki Hida, Hidetoshi Hayashi, Tadashi Maeda, Tetsuji Kawamura, Yasuharu Nakahara, Niels Claessens, Ki Hyeong Lee, Chao-Hua Chiu, Sheng-Hao Lin, Chien-Te Li, Ahmet Demirkazik, Eric Schaefer, Petros Nikolinakos, Jeffrey Schneider, Sunil Babu, Bernd Lamprecht, Michael Studnicka, Carlos Fausto Nino Gorini, Juraj Kultan, Vitezslav Kolek, Pierre-Jean Souquet, Denis Moro-Sibilot, Maya Gottfried, Egbert Smit, Kyung Hee Lee, Peter Kasan, Jozef Chovanec, Olexandr Goloborodko, Oleksii Kolesnik, Yuriy Ostapenko, Shailendra Lakhanpal, Basir Haque, Winston Chua, Joseph Stilwill, Susana Noemi Sena, Gustavo Colagiovanni Girotto, Pedro Rafael Martins De Marchi, Fabricio Augusto Martinelli de Oliveira, Pedro Dos Reis, Rositsa Krasteva, Yanqiu Zhao, Chengshui Chen, Leona Koubkova, Gilles Robinet, Christos Chouaid, Christian Grohe, Jürgen Alt, Eszter Csánky, Éva Somogyiné Ezer, Norman Isaac Heching, Young Hak Kim, Shinji Aatagi, Shoichi Kuyama, Daijiro Harada, Naoyuki Nogami, Hiroshi Nokihara, Hisatsugu Goto, Agnes Staal van den Brekel, Eun Kyung Cho, Joo-Hang Kim, Doina Ganea, Tudor Ciuleanu, Ekaterina Popova, Dina Sakaeva, Marian Stresko, Pavol Demo, Robert Godal, Yu-Feng Wei, Yen-Hsun Chen, Te-Chun Hsia, Kang-Yun Lee, Huang-Chih Chang, Chin-Chou Wang, Afshin Dowlati, Christopher Sumey, Steven Powell, Jonathan Goldman, Juan Jose Zarba, Emilio Batagelj, Andrea Viviana Pastor, Mauro Zukin, Clarissa Serodio da Rocha Baldotto, Luis Alberto Schlittler, Aknar Calabrich, Claudia Sette, Asen Dudov, Caicun Zhou, Hervé Lena, Susanne Lang, Zsuzsanna Pápai, Koichi Goto, Shigeki Umemura, Kenya Kanazawa, Yu Hara, Masahiro Shinoda, Masahiro Morise, Jeroen Hiltermann, Robert Mróz, Andrei Ungureanu, Igor Andrasina, Gee-Chen Chang, Ihor Vynnychenko, Yaroslav Shparyk, Anna Kryzhanivska, Helen Ross, Kailhong Mi, Rodney Jamil, Michael Williamson, Joseph Spahr, Zhigang Han, Mengzhao Wang, Zhixiong Yang, Jie Hu, Wei Li, Jun Zhao, Jifeng Feng, Shenglin Ma, Xiangdong Zhou, Zongan Liang, Yi Hu, Yuan Chen, Minghong Bi, Yongqian Shu, Kejun Nan, Jianying Zhou, Wei Zhang, Rui Ma, Nong Yang, Zhong Lin, Gang Wu, Jian Fang, Helong Zhang, Kai Wang, Zhendong Chen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?